Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly conventional second-line agents for hyperglycaemia in type-2 diabetes, with the Australian Diabetes Society and international guidelines elevating them into consideration as part of a patient-centred approach.

The latest Australian algorithm lists GLP-1RAs in no particular order with sodium-glucose co-transporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i) and sulfonylureas (SU) as second-line options, depending on clinical considerations and patient risks.